Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check5 days agoChange DetectedThe publications section citation for the related Oncologist article was updated to reflect the finalized issue date/details instead of an online-ahead-of-print entry. The page revision/version label was also updated (v3.5.2 to v3.5.3).SummaryDifference0.1%

- Check12 days agoChange DetectedRevision v3.5.2 was added and revision v3.5.0 was removed.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded publication reference: Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Semin Cancer Biol. 2025;109:101-124 (Epub Jan 23, 2025).SummaryDifference0.1%

- Check41 days agoChange DetectedAdded a Publications entry for the 2026 Oncologist article with PubMed auto-fill notes and removed the Revision: v3.4.3 entry.SummaryDifference0.3%

- Check48 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check77 days agoChange DetectedSite update from v3.4.1 to v3.4.2 involves minor UI/bug fixes and no substantive changes to the study record or its critical information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.